Get the Stockscreener App
81.06
3.05%
-2.55
After Hours:
81.85
0.79
+0.97%
Insmed Inc stock is traded at $81.06, with a volume of 2.69M.
It is down -3.05% in the last 24 hours and up +5.62% over the past month.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
See More
Previous Close:
$83.61
Open:
$84.46
24h Volume:
2.69M
Relative Volume:
1.51
Market Cap:
$14.67B
Revenue:
$342.96M
Net Income/Loss:
$-864.29M
P/E Ratio:
-14.61
EPS:
-5.55
Net Cash Flow:
$-636.03M
1W Performance:
+2.21%
1M Performance:
+5.62%
6M Performance:
+5.26%
1Y Performance:
+187.04%
1-Day Range:
$80.43
$84.91
1-Week Range:
$78.75
$84.91
52-Week Range:
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
81.06 | 14.67B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed (NASDAQ:INSM) Shares Gap Down on Disappointing Earnings - MarketBeat
UBS Adjusts Insmed Price Target to $105 From $84, Maintains Buy Rating -February 21, 2025 at 10:46 am EST - Marketscreener.com
UBS raises Insmed stock target to $105, maintains buy rating - Investing.com
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus.com
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates - Yahoo Finance
Insmed Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Insmed Incorporated (NASDAQ:INSM) Q4 2024 Earnings Call Transcript - Insider Monkey
Peregrine Capital Management LLC Increases Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed: Q4 Earnings Snapshot - CTPost
Insmed Incorporated (NASDAQ:INSM) Position Increased by Rhumbline Advisers - MarketBeat
Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Insmed CEO William Lewis sells $2.07 million in stock By Investing.com - Investing.com Nigeria
Insmed CEO William Lewis sells $2.07 million in stock - Investing.com India
State of New Jersey Common Pension Fund D Buys 4,438 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Insmed’s Q4 2024 results miss EPS forecast By Investing.com - Investing.com Nigeria
Cantor Fitzgerald Reaffirms "Overweight" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Earnings call transcript: Insmed's Q4 2024 results miss EPS forecast - Investing.com
Insmed falls on weak 2025 sales forecast for lead drug - TradingView
Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
INSMED Earnings Results: $INSM Reports Quarterly Earnings - Nasdaq
Insmed earnings missed by $0.14, revenue topped estimates - Investing.com
Earnings Flash (INSM) Insmed Posts Q4 Net Revenue $104.4M, vs. FactSet Est of $102.1M - Marketscreener.com
INSMED Inc SEC 10-K Report - TradingView
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update - Marketscreener.com
Insmed's chief medical officer sells $2.97 million in stock - MSN
Insmed Incorporated (NASDAQ:INSM) Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
Insmed (INSM) to Release Earnings on Thursday - MarketBeat
Insmed (NASDAQ:INSM) Hits New 52-Week HighShould You Buy? - MarketBeat
Van ECK Associates Corp Trims Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed stock soars to 52-week high, hits $82.08 - Investing.com India
Will Insmed Incorporated’s (INSM) New Drugs be Able to Peak Sales? - Yahoo Finance UK
TimesSquare Capital Management LLC Grows Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Principal Financial Group Inc. Has $125.49 Million Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Mizuho raises Insmed stock price target to $96 from $88 By Investing.com - Investing.com Canada
Rice Hall James & Associates LLC Sells 4,632 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? - MSN
Fiera Capital Corp Has $40.17 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics - MSN
Insider Selling: Insmed Incorporated (NASDAQ:INSM) CFO Sells 13,302 Shares of Stock - MarketBeat
Insmed Incorporated (NASDAQ:INSM) COO Sells $3,378,264.75 in Stock - MarketBeat
Martina M.D. Flammer Sells 37,828 Shares of Insmed Incorporated (NASDAQ:INSM) Stock - MarketBeat
Insider Sell: Sara Bonstein Sells 18,321 Shares of Insmed Inc (I - GuruFocus.com
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today - Benzinga
Peering Into Insmed's Recent Short Interest - Benzinga
Financial Advocates Investment Management Takes Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
WCM Investment Management LLC Cuts Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):